Trial · NCT02795156
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 1 | 10.3 | 95% Confidence Interval 2.87 to 24.22 | percentage of participants | |
| Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 2 | 0 | 95% Confidence Interval NA to NA | percentage of participants | |
| Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 3 | 7.1 | 95% Confidence Interval 1.5 to 19.48 | percentage of participants | |
| Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 4 | 0 | 95% Confidence Interval NA to NA | percentage of participants | |
| Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 1 | 15.4 | 95% Confidence Interval 5.86 to 30.5 | percentage of participants | |
| Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 2 | 0 | 95% Confidence Interval NA to NA | percentage of participants | |
| Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 3 | 21.4 | 95% Confidence Interval 10.3 to 36.8 | percentage of participants | |
| Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 4 | 11.1 | 95% Confidence Interval .28 to 48.2 | percentage of participants | |
| Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 1 | 2.1 | 95% Confidence Interval 1.6 to 2.8 | months | |
| Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 2 | 1.8 | 95% Confidence Interval 1.1 to 1.9 | months | |
| Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 3 | 1.9 | 95% Confidence Interval 1.8 to 3.5 | months | |
| Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 4 | 2.0 | 95% Confidence Interval 1.0 to 4.3 | months | |
| Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 1 | 3.2 | 95% Confidence Interval 2.7 to 4.4 | months | |
| Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 2 | 1.9 | 95% Confidence Interval 1.5 to 3.3 | months | |
| Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 3 | 3.1 | 95% Confidence Interval 2.3 to 4.2 | months | |
| Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations | Arm 4 | 2.8 | 95% Confidence Interval 1.8 to 8.6 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02795156/results